Skip to navigation Skip to content

Chronic myeloid leukaemia (CML) Program in Pharmaceutical Benefits Scheme (PBS) 012-18051108

Expand/Collapse all sectionsExpand all


Chronic myeloid leukaemia (CML) restriction and item codes

Do not share this attachment externally. See Freedom of Information - Information Publication Scheme.

\\INTERNAL.DEPT.LOCAL\Shared\NAT\SERDELEXCEL\WORKPRODIMP\Operation Blueprint Migration\RDT Release Icons\32w\icon-hidden-attachment.pngPBS CML restriction and item codes

Contact details

PBS Complex Drugs Programs

Forms

Chronic myeloid leukaemia - asciminib or ponatinib - initial authority application (PB171)

Chronic myeloid leukaemia - asciminib or ponatinib - continuing authority application form (PB084)

Services Australia website

Chronic myeloid leukaemia

External websites

PBS schedule for imatinib, dasatinib, nilotinib, ponatinib asciminib

FAQ from Service Officers

Table 1: see Table 2 in Processing Complex Authority Required Listings for FAQs about all Complex programs.

Item

Description

1

How to answer the prescriber type question that is not on the form?

For written ponatinib applications received via HPOS or mail, use the prescriber type displayed in OPA to complete the prescriber type question.